Back to Network
10
Shared Docs
10
Same-Page
10 / 10
Mentions
Document Mentions (10 shared documents)
2 mentions1 same-page
Page ?Same page
January 17, 2019 5:20 PM To: Jefffrey Epstein; Rich Kahn Subject: requested I forward you the below
ical industry to shift their focus from addressing =ymptoms of disease to fundamental evolutionary shortfalls. So far, I placed a =enetic vector at the National Institute of Medicine in France (that =eversed glaucoma in mice using the neuroglobin gene) under formal =icence review with a publicly traded pharma group here in the US
2 mentions1 same-page
Page ?Same page
To: Jefffrey Epstein[[email protected]]; Rich Kahn From: Lesley Groff Sent: Thur 1/17/2019
ical industry to shift their focus from addressing symptoms of disease to fundamental evolutionary shortfalls. So far, I placed a genetic vector at the National Institute of Medicine in France (that EFTA_R1_01089814 EFTA02275773 reversed glaucoma in mice using the neuroglobin gene) under formal licence review with a publicly
2 mentions1 same-page
Page ?Same page
while since I was in touch! I emailed Jeffrey and Rich last night but wasn't sure that they still use t
ical industry to shift their focus from addressing symptoms of disease to fundamental evolutionary shortfalls. So far, I placed a genetic vector at the National Institute of Medicine in France (that reversed glaucoma in mice using the neuroglobin gene) under formal licence review with a publicly traded pharma group here in the U
Sponsored
2 mentions1 same-page
Page ?Same page
while since I was in touch! I emailed Jeffrey and Rich last night but wasn't sure that they still use t
ical industry to shift their focus from addressing symptoms of disease to fundamental evolutionary shortfalls. So far, I placed a genetic vector at the National Institute of Medicine in France (that reversed glaucoma in mice using the neuroglobin gene) under formal licence review with a publicly traded pharma group here in the U
2 mentions1 same-page
Page ?Same page
I could provide in exchange for that. I am &ling Rich because I'm not sure if you still use this email?
cal industry to shift their focus from addressing symptoms of disease to fundamental evolutionary shortfalls. So far, I placed a genetic vector at the National Institute of Medicine in France (that reversed glaucoma in mice using the neuroglobin gene) under formal licence review with a publicly traded pharma group here in the U
2 mentions1 same-page
Page ?Same page
could provide in exchange for that. I am cc'ing Rich because I'm not sure if you still use this email?
cal industry to shift their focus from addressing symptoms of disease to fundamental evolutionary shortfalls. So far, I placed a genetic vector at the National Institute of Medicine in France (that reversed glaucoma in mice using the ncuroglobin gene) under formal licence review with a publicly traded pharma group here in the
Sponsored
2 mentions1 same-page
Page ?Same page
ff To: Jefffrey Epstein <[email protected]>, Rich Kahn < Subject: Date: Thu, 17 Jan 2019 17:19:49
ical industry to shift their focus from addressing symptoms of disease to fundamental evolutionary shortfalls. So far, I placed a genetic vector at the National Institute of Medicine in France (that reversed glaucoma in mice using the neuroglobin gene) under formal licence review with a publicly traded pharma group here in the US
2 mentions1 same-page
Page ?Same page
while since I was in touch! I emailed Jeffrey and Rich last night but wasn't sure that they still use t
ical industry to shift their focus from addressing symptoms of disease to fundamental evolutionary shortfalls. So far, I placed a genetic vector at the National Institute of Medicine in France (that reversed glaucoma in mice using the neuroglobin gene) under formal licence review with a publicly traded pharma group here in the US
2 mentions1 same-page
Page ?Same page
I could provide in exchange for that. I am cc'ing Rich because I'm not sure if you still use this email
ical industry to shift their focus from addressing symptoms of disease to fundamental evolutionary shortfalls. So far, I placed a genetic vector at the National Institute of Medicine in France (that reversed glaucoma in mice using the neuroglobin gene) under formal licence review with a publicly traded pharma group here in the U
Sponsored
2 mentions1 same-page
Page ?Same page
From: To: Rich Kahn Subject: Re: Date: Thu, 17 Jan 2019 22:20:
ical industry to shift their focus from addressing symptoms of disease to fundamental evolutionary shortfalls. So far, I placed a genetic vector at the National Institute of Medicine in France (that reversed glaucoma in mice using the neuroglobin gene) under formal licence review with a publicly traded pharma group here in the U
Sponsored
Mutual Connections (7)
Entities connected to both Marc Rich and the National Institute of Medicine
